Salarius Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2020-12-02

Reporting Person: Rosenblum Mark J (Exec VP Finance, CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-02	Stock Option (right to buy)	$0.74	A	80000	Acquired	2030-12-01	Common Stock (80000.0)	Direct

Footnotes

F1: 25% of the options are fully vested on December 1, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter.